Abacus Life, Inc. (NASDAQ:ABL – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $9.76, but opened at $8.38. Abacus Life shares last traded at $8.63, with a volume of 173,238 shares.
Analyst Ratings Changes
Separately, B. Riley began coverage on Abacus Life in a research report on Friday, May 31st. They set a “buy” rating and a $16.00 target price on the stock.
Check Out Our Latest Stock Report on Abacus Life
Abacus Life Price Performance
Abacus Life (NASDAQ:ABL – Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported $0.11 earnings per share (EPS) for the quarter. The firm had revenue of $21.49 million for the quarter. Abacus Life had a return on equity of 4.96% and a net margin of 0.11%. As a group, equities research analysts predict that Abacus Life, Inc. will post 0.52 earnings per share for the current year.
Hedge Funds Weigh In On Abacus Life
Several institutional investors and hedge funds have recently added to or reduced their stakes in ABL. Barclays PLC acquired a new position in Abacus Life during the 3rd quarter worth approximately $47,000. Quarry LP purchased a new stake in shares of Abacus Life during the 4th quarter worth approximately $463,000. Finally, Inscription Capital LLC purchased a new stake in shares of Abacus Life during the 1st quarter worth approximately $137,000.
Abacus Life Company Profile
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
Featured Stories
- Five stocks we like better than Abacus Life
- What Are Growth Stocks and Investing in Them
- McDonald’s Stock: Balancing Value and Innovation
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 6/17 – 6/21
- What is the Dow Jones Industrial Average (DJIA)?
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Abacus Life Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abacus Life and related companies with MarketBeat.com's FREE daily email newsletter.